Search company, investor...

Founded Year

1999

Stage

Unattributed VC - II | Alive

Total Raised

$124.63M

Last Raised

$1.68M | 14 yrs ago

About Locus Pharmaceuticals

Locus Pharmaceuticals is a company focused on the biotechnology sector, specifically in the area of protein and antibody discovery. The company offers a range of products including proteins, mouse monoclonals, and rabbit antibodies, which are used in various research and scientific applications. The primary customers of Locus Pharmaceuticals are likely to be in the research and healthcare sectors. It was founded in 1999 and is based in Blue Bell, Pennsylvania.

Headquarters Location

Four Valley Square 512 E Township Line RD

Blue Bell, Pennsylvania, 19422,

United States

215-358-2028

Loading...

Loading...

Locus Pharmaceuticals Patents

Locus Pharmaceuticals has filed 24 patents.

The 3 most popular patent topics include:

  • data modeling
  • data management
  • database management systems
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/24/2020

5/23/2023

Data management, Database management systems, Data modeling, Machine learning, Databases

Grant

Application Date

3/24/2020

Grant Date

5/23/2023

Title

Related Topics

Data management, Database management systems, Data modeling, Machine learning, Databases

Status

Grant

Locus Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Locus Pharmaceuticals founded?

    Locus Pharmaceuticals was founded in 1999.

  • Where is Locus Pharmaceuticals's headquarters?

    Locus Pharmaceuticals's headquarters is located at Four Valley Square, Blue Bell.

  • What is Locus Pharmaceuticals's latest funding round?

    Locus Pharmaceuticals's latest funding round is Unattributed VC - II.

  • How much did Locus Pharmaceuticals raise?

    Locus Pharmaceuticals raised a total of $124.63M.

  • Who are the investors of Locus Pharmaceuticals?

    Investors of Locus Pharmaceuticals include Prism VentureWorks, Origin Capital Group, Cooper Hill Partners, Amerindo Investment Advisors, Tredegar and 20 more.

  • Who are Locus Pharmaceuticals's competitors?

    Competitors of Locus Pharmaceuticals include Inhibikase Therapeutics, Tetraphase Pharmaceuticals, Viamet Pharmaceuticals, CoLucid Pharmaceuticals, Acetylon Pharmaceuticals and 7 more.

Loading...

Compare Locus Pharmaceuticals to Competitors

Can-Fite BioPharma Logo
Can-Fite BioPharma

Can-Fite BioPharma is a biopharmaceutical company focused on the discovery and clinical development of proprietary drugs for inflammatory, liver, and metabolic diseases. The company's main offerings include oral drugs that target the A3 adenosine receptor to modulate inflammatory and cancer pathways, with a pipeline of drug candidates in Phase II and Phase III clinical trials. Can-Fite's products are designed to have anti-inflammatory and anti-cancer effects by binding to the A3AR and affecting the NF-kB and Wnt signal transduction pathways. It is based in Petach-Tikva, Israel.

A
Affinium Pharmaceuticals

Affinium Pharmaceuticals is a specialty pharmaceutical company developing a class of antibiotics that target the bacterial fatty acid synthesis (FASII) pathway. AFN-1252, the company's lead clinical compound, is a highly-potent, small molecule antibiotic for both oral and IV treatment of staphylococcal infections, including MRSA and all other drug-resistant strains.

A
Ancora Pharmaceuticals

Ancora Pharmaceuticals is a company focused on glycobiology within the pharmaceutical industry. The company's main offerings include the development of synthetic carbohydrates, which are used in the creation of vaccines. It was founded in 2001 and is based in Woburn, Massachusetts.

U
Ulysses Pharmaceuticals

Ulysses Pharmaceuticals is dedicated to the discovery and development of safe antimicrobial agents for the treatment of severe and recurrent infections occurring in humans. The Company intends to become an industry leader in the antiinfective field through the development of new antibiotics including some acting as Trojan Horses that take advantage of essential microbial transport systems to specifically enter targeted pathogens. Ulysses concentrates on the development of advanced hit and lead compounds with promising features and characteristics that are indicative of potent antibacterial agents with potential for strong market penetration.

M
Mimetix Pharmaceuticals

Free Radical Scavengers developed from Duke's BME Department for treating and preventing diseases from occurring.

M
MuriGen

MuriGen is building a portfolio of drugs for unmet medical needs across a number of therapeutic areas including cancer, arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.